Best Antidepressant for Depression with Insomnia
For an adult with depression and insomnia, mirtazapine is the most appropriate first-line antidepressant because it simultaneously treats both conditions through 5-HT₂ receptor blockade, producing significant sleep improvements (shortened sleep-onset latency, increased total sleep time, improved sleep efficiency) while delivering full antidepressant efficacy at therapeutic doses of 15–45 mg. 1
Why Mirtazapine Is the Optimal Choice
Mirtazapine blocks 5-HT₂ receptors, which are responsible for the insomnia and sleep architecture disruption caused by SSRIs and SNRIs; this mechanism directly addresses both depression and insomnia without requiring a second medication. 1
In depressed patients, mirtazapine produces marked shortening of sleep-onset latency, increases total sleep time, and leads to significant improvement in sleep efficiency—effects that begin within the first week of treatment. 1
The sedating effect is paradoxically stronger at lower doses (7.5–15 mg) due to predominant histamine H₁ antagonism, but full antidepressant efficacy requires 15–45 mg daily; therefore, start at 15 mg at bedtime and titrate to 30–45 mg based on mood response. 12
Unlike SSRIs/SNRIs (fluoxetine, paroxetine, sertraline, venlafaxine), which stimulate 5-HT₂ receptors and worsen insomnia in 30–40% of patients even during maintenance treatment, mirtazapine improves sleep from the outset. 31
Why Other Antidepressants Are Inferior for This Indication
SSRIs and SNRIs (Fluoxetine, Paroxetine, Sertraline, Venlafaxine)
SSRIs and SNRIs activate 5-HT₂ receptors, causing insomnia, increased sleep-onset latency, reduced slow-wave sleep, and REM sleep disruption; 30–40% of patients require co-prescription of hypnotics or low-dose trazodone to manage treatment-emergent insomnia. 31
Paroxetine showed modest sleep improvements in two small trials (60 and 27 participants), but these effects were inconsistent and not replicated in larger studies; fluoxetine showed no sleep benefit. 4
Trazodone (Often Used Off-Label for Insomnia)
Trazodone at typical insomnia doses (50 mg) produces only a 10-minute reduction in sleep-onset latency and 8 minutes less wake after sleep onset, with no improvement in subjective sleep quality; harms outweigh benefits. 24
To reach therapeutic antidepressant doses (150–300 mg), trazodone must be escalated far beyond the 50 mg typically used for sleep, and even then it is less effective than mirtazapine for both depression and insomnia. 2
The American Academy of Sleep Medicine explicitly recommends against trazodone for insomnia treatment due to minimal efficacy and high adverse-event rates (75% in older adults, including daytime sedation, dizziness, and priapism). 2
Tricyclic Antidepressants (Amitriptyline, Doxepin)
Low-dose doxepin (3–6 mg) is effective for sleep maintenance but provides no antidepressant effect at these doses; full antidepressant dosing (≥75 mg) causes severe anticholinergic side effects (dry mouth, urinary retention, confusion, constipation) that limit tolerability. 24
Amitriptyline has strong anticholinergic burden and is not recommended as first-line for depression with insomnia; secondary amines (nortriptyline, desipramine) have fewer anticholinergic effects but still lack the favorable sleep profile of mirtazapine. 5
Implementation Algorithm
Step 1: Initiate Mirtazapine with Concurrent CBT-I
Start mirtazapine 15 mg at bedtime (the lowest dose that provides both sedation and antidepressant efficacy); counsel the patient that sedation will be immediate but mood improvement requires 2–4 weeks. 1
Simultaneously initiate Cognitive Behavioral Therapy for Insomnia (CBT-I), which is the first-line treatment for chronic insomnia and provides superior long-term outcomes compared with medication alone; core components include stimulus control, sleep restriction, cognitive restructuring, and sleep-hygiene education. 26
Step 2: Titrate Mirtazapine Based on Mood Response
After 2 weeks, if depressive symptoms persist, increase mirtazapine to 30 mg at bedtime; if still insufficient after another 2 weeks, increase to 45 mg (maximum dose). 1
Do not reduce the dose to 7.5 mg solely for sedation, as this subtherapeutic dose will not treat depression; the sleep benefit is maintained at higher doses through continued 5-HT₂ blockade. 1
Step 3: Reassess at 4–6 Weeks
Evaluate both mood symptoms (using PHQ-9 or similar) and sleep parameters (sleep-onset latency, total sleep time, nocturnal awakenings, daytime functioning) to determine whether mirtazapine is adequately addressing both conditions. 2
If insomnia persists despite mirtazapine optimization and CBT-I, add low-dose doxepin 3–6 mg at bedtime (not trazodone) for additional sleep-maintenance support; this combination is safe and does not require dose adjustment. 25
Step 4: Long-Term Management
Continue mirtazapine for at least 6–12 months after remission of depression to prevent relapse; the sleep benefit typically persists throughout treatment. 1
Maintain CBT-I techniques indefinitely, as behavioral interventions provide sustained sleep improvements that persist after medication discontinuation. 26
Medications to Avoid in Depression with Insomnia
Do not use SSRIs or SNRIs as monotherapy unless the patient has failed mirtazapine or has contraindications (e.g., significant weight gain concerns); if an SSRI/SNRI is necessary, co-prescribe low-dose doxepin 3–6 mg (not trazodone) from the outset. 31
Do not prescribe trazodone for depression with insomnia, as it requires doses of 150–300 mg for antidepressant effect (far above the 50 mg used for sleep), and even then it is less effective than mirtazapine for both indications. 24
Do not use benzodiazepines or Z-drugs (zolpidem, eszopiclone) as first-line adjuncts to antidepressants, as they carry risks of dependence, falls, cognitive impairment, and do not address the underlying sleep disruption caused by depression. 26
Do not use over-the-counter antihistamines (diphenhydramine, doxylamine) for insomnia in depressed patients, as they lack efficacy, cause anticholinergic side effects, and develop tolerance within 3–4 days. 26
Do not use antipsychotics (quetiapine, olanzapine) for insomnia in depression, as they have weak evidence for sleep benefit and significant risks (weight gain, metabolic syndrome, extrapyramidal symptoms). 26
Common Pitfalls to Avoid
Prescribing an SSRI/SNRI without addressing insomnia upfront leads to treatment-emergent insomnia in 30–40% of patients, poor adherence, and increased risk of relapse. 31
Using subtherapeutic doses of mirtazapine (7.5 mg) for depression will not treat the mood disorder, even though it provides sedation; always use ≥15 mg for antidepressant efficacy. 1
Adding trazodone 50 mg to an SSRI/SNRI for insomnia is common practice but not evidence-based; low-dose doxepin 3–6 mg is superior for sleep maintenance and has fewer adverse effects. 24
Failing to implement CBT-I alongside pharmacotherapy results in less durable sleep improvements and higher rates of medication dependence. 26
Continuing hypnotics (benzodiazepines, Z-drugs) long-term without addressing the underlying depression perpetuates insomnia and increases risks of tolerance, dependence, falls, and cognitive impairment. 26